Microvascular Dysfunction

Accurate diagnosis of microvascular conditions can change clinical outcomes

Better efficacy of existing emerging therapies

Proven existing and emerging MVO/MVD therapies can have dramatically better efficacy if targeted with an accurate diagnostic first

Screening patients that would benefit most, with far greater practicality

Patient stratification

Clinical studies and publications have shown that MVO/MVD diagnosis can improve outcomes with early detection and optimal medical therapy

New guidelines, reimbursement and clinical practice post diagnosis

Future Innovation

With an explosion in attention to microvascular disorders and recognition as the next frontier in improving cardiovascular outcomes, future innovation in therapy options will undoubtedly expand which require a gold standard diagnostic.

With the microvascular “Catch 22” solved, research and funding will flow to therapies

The Controlled Flow Infusion (CoFI) for MVO

CorFlow has developed the Controlled Flow Infusion (CoFI) System for MVO: Early diagnosis and targeted delivery of treatment in the cath lab, within minutes

Diagnosis of MVO in the cathlab

In-stent occlusion & controlled infusion + measurement of back-pressure response in less than 2 minutes

Early assessment of microvascular status.

Targeted delivery of therapeutic agents

In-stent occlusion & intracoronary infusion of therapeutic agents in less than 10 minutes.

Delayed wash-out, increased dwelling time, “massage” of drug into obstructed vessels

CorFlow CoFI console Gen 2

  • MVO diagnosis directly in the cathlab within minutes – a market first
  • Targeted delivery of therapeutic agents directly after MVO diagnosis – a market first
  • Fully integrated system – learnings implemented from Gen 1 and FIH clinical study
  • Ability to upgrade software as a platform with AI capability
  • CoFI infusion cassette for fast setup and sterile, single-use design

CorFlow CoFI catheter Gen 2

  • Proprietary occlusion-infusion catheter
  • 6 French guide catheter compatibility for radial or femoral approach
  • Compatible with stent sizes 2.75 – 5mm

Benefit For Physical Mental
and Virtual Care

Microcirculatory / microvascular dysfunction remains an area of massive unmet need in >20M people annually – it accounts for 1/6 below-the-knee amputations, 1/4 ischemic stroke patients, and 1/2 of all INOCA patients (70% female)

Reperfusion injury occurs in multiple organs as “collateral damage” when restoring blood flow

The global reperfusion market today is highly fragmented, $1.4B with a 5% CAGR and ripe for disruption

CorFlow represents a new approach, including next generation AI utilization for both diagnostics and therapy delivery with drug/device combinations not previously feasible

Coronary – STEMI –MVO / NSTEMI

INOCA and MINOCA – ischemic non obstructed coronary arteries and myocardial infarcted non obstructed coronary arteries

Pulmonary Embolism

Pulmonary Hypertension

Below the Knee Peripheral Vascular disease

Chronic kidney disease

Stroke

Dementia

The CorFlow MVO Coronary Market Potential

Total Angina
0 M
Unstable and Refractory Angina
0 K
NSTEMI PCI
0 M
STEMI PCI
0 K